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Mutations in GlyR α1 or β subunit genes in humans and rodents lead to severe startle
disease characterized by rigidity, massive stiffness and excessive startle responses
upon unexpected tactile or acoustic stimuli. The recently characterized startle disease
mouse mutant shaky carries a missense mutation (Q177K) in the β8-β9 loop within
the large extracellular N-terminal domain of the GlyR α1 subunit. This results in
a disrupted hydrogen bond network around K177 and faster GlyR decay times.
Symptoms in mice start at postnatal day 14 and increase until premature death of
homozygous shaky mice around 4–6 weeks after birth. Here we investigate the in vivo
functional effects of the Q177K mutation using behavioral analysis coupled to protein
biochemistry and functional assays. Western blot analysis revealed GlyR α1 subunit
expression in wild-type and shaky animals around postnatal day 7, a week before
symptoms in mutant mice become obvious. Before 2 weeks of age, homozygous
shaky mice appeared healthy and showed no changes in body weight. However,
analysis of gait and hind-limb clasping revealed that motor coordination was already
impaired. Motor coordination and the activity pattern at P28 improved significantly
upon diazepam treatment, a pharmacotherapy used in human startle disease. To
investigate whether functional deficits in glycinergic neurotransmission are present prior
to phenotypic onset, we performed whole-cell recordings from hypoglossal motoneurons
(HMs) in brain stem slices from wild-type and shaky mice at different postnatal stages.
Shaky homozygotes showed a decline in mIPSC amplitude and frequency at P9-P13,
progressing to significant reductions in mIPSC amplitude and decay time at P18-24
compared to wild-type littermates. Extrasynaptic GlyRs recorded by bath-application
of glycine also revealed reduced current amplitudes in shaky mice compared to
wild-type neurons, suggesting that presynaptic GlyR function is also impaired. Thus, a
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distinct, but behaviorally ineffective impairment of glycinergic synapses precedes the
symptoms onset in shaky mice. These findings extend our current knowledge on startle
disease in the shaky mouse model in that they demonstrate how the progression of GlyR
dysfunction causes, with a delay of about 1 week, the appearance of disease symptoms.
Keywords: glycine receptor, startle disease, β8-β9 loop, mouse model, fast decay, shaky
INTRODUCTION
Glycinergic inhibition is prominent in brain stem and spinal
cord, where it is involved in essential processes such as
motor control (Lynch, 2004), inflammatory pain sensitization
(Harvey et al., 2004) and rhythmic breathing (Manzke et al.,
2010). GlyR defects have also been implicated in startle disease
(Harvey et al., 2008) autism spectrum disorder (Pilorge et al.,
2015; Zhang et al., 2017) and panic disorders (Deckert et al.,
2017). Glycine receptors (GlyRs) are integrated into the nerve-
muscle circuit, where they are postsynaptically expressed in
the membrane of motoneurons. Upon glycine-release from
neighboring inhibitory interneurons, GlyRs are activated and
chloride ion flux leads to hyperpolarization of the motoneurons,
regulating excitation of the motoneurones and thus controlling
muscle contraction (Schaefer et al., 2012). Defects in glycinergic
transmission are the underlying cause of the neurological motor
disorder hyperekplexia (OMIM 149400, startle disease, stiff baby
syndrome). Human hyperekplexia is caused by mutations in
the GLRA1, GLRB, or SLC6A5 genes, encoding GlyR α1 and β
subunits and the glycine transporter GlyT2. Symptoms in human
hyperekplexia range from exaggerated startle reactions - due
to unexpected acoustic or tactile stimuli - to muscle stiffness,
apnea, and loss of postural control. Individuals with startle
disease are typically treated with low doses of the benzodiazepine
clonazepam, a positive allosteric modulator of GABAA receptors
(Christian et al., 2013).
Mice carrying Glra1 (spasmodic, oscillator, shaky, nmf11,
cincinnati) or Glrb (spastic) mutations have served as models of
startle disease. However, it is noteworthy that disease symptoms
are typically severe in most mouse startle disease models.
Phenotypic symptoms typically start at day P14 and increase
during the second and third week of life until premature
death between weeks 4 and 6. Spasmodic mice harbor the
missense mutation A52S in the GlyR α1 subunit A loop, leading
to decreased ligand affinity and potency (Ryan et al., 1994).
Homozygous cincinnati and oscillator mice represent GlyR α1
subunit null mutations, the former caused by duplication of
Glra1 exon 5, the latter due to a microdeletion in exon 8, both
resulting in mRNA mis-splicing and truncated non-functional
GlyR α1 subunits (Buckwalter et al., 1994; Holland et al.,
2006). Spastic mice result from aberrant splicing of the GlyR β
subunit mRNA, due to a LINE-1 element insertion in intron 6
Abbreviations: Glycine receptors (GlyRs), glycine transporter 2 (GlyT2), Cys-
loop receptors (CLRs), extracellular domains (ECDs), wild type (Glra1+/+), shaky
mice (Glra1sh/sh), miniature inhibitory postsynaptic currents (mIPSCs), artificial
cerebrospinal fluid (aCSF), kynurenic acid (KA), bicuculline (BIC), tetrodotoxin
(TTX), Stationary noise analysis (SNA), hypoglossal motoneurons (HM).
(Becker et al., 2012). Nmf11 harbors a GlyR α1 subunit N46K
missense mutation, resulting in a reduction in the potency of
the transmitter glycine and rapid deactivation mutant GlyR
currents (Wilkins et al., 2016). Lastly, the recently characterized
spontaneous mouse mutant shaky carries a missense mutation
Q177K in the β8-β9 loop of the GlyR α1 subunit extracellular
domain (Schaefer et al., 2017). Few of these mutants have
been studied using ex vivo electrophysiological approaches.
Recordings from hypoglossal motoneurons of adult oscillator
or spastic mice have revealed reduced amplitude and frequency
of mIPSCs (Graham et al., 2003, 2006). GlyR defects have
also been studied in zebrafish, where some GlyR genes have
undergone duplication during evolution (Hirata et al., 2005).
In this model organism, mutation of the GlyR β subunit
gene (Hirata et al., 2005) or morpholino knockdown of
the GlyR α1 or α4a subunits also leads to defective startle
and escape responses (Ganser et al., 2013; Leacock et al.,
2018).
GlyRs belong to the superfamily of Cys-loop receptors (CLRs)
and are pentameric receptor complexes. At synapses, these
pentameric receptors are composed of α- and β- subunits
anchored via the scaffolding protein gephyrin. Various ion
channel stoichiometries, e.g., 3α:2β or 2α:3β subunits have been
described (Yang et al., 2012; Patrizio et al., 2017). The large
extracellular domains (ECDs) form ligand-binding sites at the
interface between adjacent subunits, which are constituted by
loops A-C from one subunit (principle subunit refers to (+) site)
and loops D-F (loop F is further referred to as loop β8-β9, (–) site
refers to complementary subunit) from the neighboring subunit
(Hibbs and Gouaux, 2011). Several in vitro studies have revealed
that GlyR function is highly dependent on ECD loop structures
of the receptor, e.g., phenylalanine 159, which is localized in
loop B was shown to contribute to cation-pi interaction with
the incoming ligand. This process is essential prior to channel
opening (Pless et al., 2011). Moreover, loop C plays a role in
transmitting the activation signal to the rest of the channel. This
loop undergoes large rearrangements upon ligand binding, which
is further translated to transmembrane (TM) domains (Althoff
et al., 2014). Loop β8-β9 has been suggested to play a major
role in linking ligand binding to channel opening. The published
structural model for GlyR α1 showed a coupling of movements
within the ECDs, including the β8-β9 loop, proceeding to the TM
helices resulting in their tilting and enabling ion channel opening
and closing (Du et al., 2015; Huang et al., 2015). The shaky
mutation, Q177K, localized in the β8-β9 loop represents the first
in vivomodel where this ECD loop structure has been disrupted.
Affected mice show largely impaired glycinergic function, which
is in line with the known structural importance of the β8-β9
loop.
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The GlyR α1β subtype is the most abundant adult isoform
in spinal cord and brain stem nuclei. It is known, that all
GlyR subunits undergo developmental regulation, with α1 and β
subunit expression increasing from birth to P19 in spinal cord
and brain stem nuclei (e.g., hypoglossal nuclei, pre-Bötzinger
neurons). By contrast, α2 and α3 subunits decrease after a first
peak at postnatal day 7–10 (Liu andWong-Riley, 2013). Variation
in developmental regulation of GlyR subunit expression between
humans and mice account for differences in disease onset and
progression. In humans, startle disease symptoms are evident
during the first week of life, whereas in rodents symptoms are
first observed during the second postnatal week around P14
(Ryan et al., 1992; Buckwalter et al., 1994). However, since
GlyR gene expression is already evident in mice by P7, it
is possible that functional deficits are already present within
the second postnatal week before the onset of severe disease
symptoms.
Here, we explored the importance of the shaky Q177K
mutation focusing on the onset and progression of behavioral
symptoms and functional GlyR deficits. Our data show that the
Q177K mutation in the GlyR α1 subunit β8-β9 loop impairs
motor coordination in mice and in zebrafish. GlyR α1 subunit
expression starts 7 days prior to onset of the startle phenotype
in mice. This is paralleled by functional deficits in glycinergic
neurotransmission that become obvious at P9 and increase
during disease progression. In conclusion, functional defects at
the molecular level are present days before the disease phenotype
is evident.
MATERIALS AND METHODS
Mouse Lines
The shakymutant mouse strain arose as a spontaneous mutation
in the animal colony of C. Paige (University Health Network
Research, Toronto, Canada) in a mixed 129X1/SvJ / C57BL6
strain. Mice were transferred into the animal facility of the
Institute for Clinical Neurobiology (Würzburg, Germany),
where mice were housed under pathogen-free conditions; water
and food were available ad libitum. Experiments were approved
by the local veterinary authority (Veterinaeramt der Stadt
Wuerzburg), the Ethics Committee of Animal Experiments,
i.e., Regierung von Unterfranken, Würzburg (License number
55.2-2531.01-09/14) and the University Health Network’s
Institutional Animal Facility. Spasmodic and oscillator mice
were a gift from C.-M. Becker (Institute of Biochemistry,
Friedrich-Alexander-University Erlangen-Nürnberg,
Germany).
Behavioral Analysis
The neuromotor phenotype of homozygous Glra1sh/sh mice was
investigated by overall visual examination of the activity pattern
including: hind-feet clasping, righting ability, time spent on back,
time spent upright, resting, grooming, eating, assessment of gait
by footprint recordings, body weight. Videos were recorded with
the multi conditioning System from TSE (256060 series, Bad
Homburg, Germany). Video 1: Impaired righting behavior and
typical hind limb clasping at the onset of symptoms at P14.
Video 2: Severe neuromotor phenotype at P22 with exaggerated
startle response accompanied by rigidity of extremities and the
back upon touching. The animals were monitored with the TSE
MCS FCS – SQ MED software. Body weight was checked over
a period of 6 weeks every 2–3 days. Diazepam was injected
intraperitoneally at a concentration of 0.5 mg/kg in a total
volume of 100 µl of sterile PBS. Control animals were injected
with PBS.
GlyR α1 Subunit Transcript Analysis
Total RNA was isolated from spinal cord of a 3-week old
shaky mutant and littermate controls using Trizol reagent
(Gibco/ThermoFisher Scientific, Waltham, Massachusetts,
USA). cDNA synthesis was performed using Superscript IITM
(Invitrogen, Carlsbad, California, USA). RT-PCR reaction mixes
for β-actin and GlyR α1 subunit exons 1–9 contained 1x PCR
buffer, 1.5mM MgCl2, 0.2mM of each dNTP, 10 pmol of each
primer (β-actin for: 5′-TCCCTGGAGAAGAGCTACGA-3′,
rev: 5′-ATCTGCTGGAAGGTGGACAG-3′; GlyRex1 for:
5′-CAGCACTAGAATCTGGAAGATG-3′, GlyRex9 rev: 5′-
CCATAGGCAGAGAAGTTGAAG-3′) and 1U of Platinum Taq
DNA Polymerase (Invitrogen, Carlsbad, California, USA). The
PCR program consisted of 95◦C 5min followed by 32 × 95◦C
30 s, 59◦C 30 s and 72◦C 1min.
PCR Genotyping Shaky Mice
Biopsies were taken from earmarks and digested overnight
in 800 µl of TENS buffer (50mM Tris, pH 8.0, 100mM
EDTA, 100mM NaCl, 1% (w/v) SDS, 0.5 mg/ml proteinase
K) at 55◦C. The genomic DNA was extracted via isopropanol
precipitation. For shaky mice a 185 bp fragment was amplified,
covering the entire exon 6. PCR reactions were set up as
follows: 1.25mM dNTPs, 25mM MgCl2, 5x GoGreen buffer,
1U GoTaq polymerase 5 pmol/µl primers contained 10 pmol
of each primer (Forward: 5′CTGAGTTCTCGCTGACCGAGC3′
Reverse: 5′CACCTGTGTTGTAGTGCTTG3′). A PCR program
of 5min 95◦C, 32 × 20 s 95◦C, 20 s 59◦C and 20 s 72◦C
was used. The product was subsequently digested with the
restriction endonuclease HpyCH4V (New England Biolabs,
Ipswich, Massachusetts, USA), which is only able to cut wild-type
and not shaky PCR product. For analysis, all PCRs were loaded on
2–4% agarose gels.
Membrane Preparation
For membrane protein analysis, crude cell membranes were
prepared from mouse tissues (Sontheimer et al., 1989).
Western Blot
For SDS-PAGE, 11% polyacrylamide gels were freshly prepared,
followed by Western blot on nitrocellulose membranes (GE
Healthcare, Little Chalfont, Great Britain). Membranes were
blocked for 1 h with 5% BSA in TBS-T (TBS with 1% Tween
20). Primary antibodies were incubated overnight at 4◦C. GlyR
proteins were detected with the GlyR α1 specific antibodymAb2b
(cat. no. 146003 1:1,500, Synaptic Systems, Göttingen, Germany).
β-Actin (cat. no. GTX26276, WB 1:5,000, GeneTex/Biozol,
Eching, Germany) served as loading control. Signals were
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detected using the ECL plus system (GE Healthcare, Little
Chalfont, Great Britain).
Brain Homogenates
Glra1+/+ and Glra1sh/sh mice were sacrificed at 3–4 weeks of
age. GlyR α1 Western blot analysis of combined spinal cord
and whole brain samples was performed as previously described
(Traka et al., 2006), using a polyclonal antibody against the
N-terminus of the 48 kDa GlyR α1 subunit (dilution 1:200,
Merck Millipore, Darmstadt, Deutschland). β-actin (cat. no.
GTX26276, WB 1:5,000, GeneTex/Biozol, Eching, Germany)
served as loading control. Data analysis of Western blots: The
image quantification was performed using the ImageJ software
(1.51)/Fiji (Schindelin et al., 2015). The data were analyzed using
Student’s t-test (analysis of variance) or one-way ANOVA, and
values below p< 0.05 were considered significant. The values are
displayed as means± standard deviation (±SD).
Zebrafish Assay
Zebrafish were bred and assayed according to the guidelines set
forth by Aoyama Gakuin University. Antisense morpholino
oligonucleotides that target Dhx37 (MO2-dhx37: 5′-
ATCAAGTGTTTTACCTTGTTGCGGA-3′) were coinjected
with or without zebrafish wild-type or mutant GlyRα1 RNA into
zebrafish embryos at 1–2 cell stage (Hirata et al., 2013). Larval
behaviors were observed at 48 h post-fertilization under a stereo
microscope Leica MZ16F. Tactile stimuli were delivered to the
tail using a pair of forceps. Responses of larvae were classified
as follows: normal (a lateral turn and subsequent swimming),
mildly affected (a dorsal bend followed by swimming of more
than 2 cm), severely affected (a dorsal bend without escape
swimming) according to a previous report (Hirata et al., 2013).
Counting of Motoneurons
To count motoneurons from the brain stem, mice were deeply
anesthetized and transcardially perfused. Brain slices were
stained with cresyl violet and motoneurons were counted in
facial nerve in 15–16 sections of every tenth section of the
brain stem. The raw counts were corrected for double counting
of split nucleoli as described (Masu et al., 1993). Differences
between groups were evaluated with Student’s t-test (unpaired,
significance level ∗p < 0.05). The Graphics Prism Program
(Graph Pad Software Inc., San Diego, California, USA) was used
for calculation and data presentation.
Brain Stem Slice Preparation and
Whole-Cell Recordings
Electrophysiological experiments were performed on brain
stem slices from 9 to 24 day old mice. After anesthesia and
decapitation, brain stems were rapidly removed and immersed
in ice-cold ‘high sucrose’ artificial cerebrospinal fluid (aCSF)
containing (in mM): 75 sucrose, 125 NaCl, 3 KCl, 0.3 CaCl2, 7
MgCl2, 1.25 NaH2PO4, 25 NaHCO3, 30 D-glucose and bubbled
with carbogen (95% O2/5% CO2, pH 7.4). Transverse slices
250µm thick containing the hypoglossal motor nucleus (XIIn)
were cut, transferred to warmed (35◦C) high-sucrose aCSF
for 10min and kept thereafter in normal aCSF (see below)
at room temperature for at least 1 h before being transferred
individually to a submerged recording chamber, which was
perfused with normal aCSF of the following composition (in
mM) 125 NaCl, 3 KCl, 1.5 CaCl2, 1 MgCl2, 1.25 NaH2PO4, 25
NaHCO3 and 30 D-glucose at 30
◦C, gassed with 95%O2/5% CO2
(pH 7.4). Whole-cell recordings from neurons in hypoglossal
motor nucleus were performed with patch pipettes filled with
internal solution composed of (in mM): 130 CsCl, 3 MgCl2,
5 EGTA, 5 Hepes, 2 Na2-ATP, 0.3 Na3-GTP, and 5 QX-314
(pH 7.3). The electrode resistance ranged from 3 to 5 M
when filled with internal solution. Whole-cell currents were
recorded at a holding potential of −70mV (corrected for liquid
junction potential), filtered (2 kHz) and sampled at 20 kHz using
aMulticlamp 700B amplifier in conjunction with Digidata 1440A
interface and pClamp10 software (Molecular Devices, Silicon
Valley, California, USA).
Miniature glycinergic IPSCs (mIPSCs) were
pharmacologically isolated by perfusing slices with aCSF
containing the ionotropic glutamate receptor antagonist
kynurenic acid (KA, 2mM), GABAA receptor antagonist
bicuculline methiodide (BIC, 20µM) and tetrodotoxin (TTX,
1µM). Individual events were detected with Clampfit software
(Molecular Devices, Silicon Valley, California, USA) using a
template method with amplitude threshold set to 5–6∗ σnoise.
Peak amplitude, 10–90% rise time and 90–10% decay time
were measured and averaged over a minimum of 20 events.
For mIPSC kinetics only non-overlapping events with relatively
fast rise times (<2ms) and a smooth decay were included in
the analysis. For dose-response curves, glycine (10–1,000µM)
was bath applied in the presence of TTX (1µM), KA (2mM)
and BIC (10µM). The peak current at a given concentration
was averaged from values measured in individual neurons,
plotted against glycine concentration, and fitted with a sigmoidal
function for determination of EC50. Stationary noise analysis
(SNA) was performed on glycine-evoked current responses with
the help of the analysis software WinEDRv.3.5 (John Dempster,
Strathclyde Software, University of Strathclyde, Glasgow, Great
Britain) using the recorded DC current signal and a band-pass
filtered AC-coupled version of this signal. Mean current (Im)
and current variance (σ2) were computed from the DC and AC
traces, respectively, for records where the whole-cell current was
slowly changing due to glycine application. After subtraction of
the control background variance, we fitted the variance-mean
curve with a parabolic function. Estimates of the single channel
current Iu were obtained from the number of channels (Nc)
and the open probability (Po) according to: σ
2 = I2uNcPo(1-Po)
(1) and Im = IuNcPo (2), which combine to give the parabolic
function: σ2 (Im) = Iu Im–Im 2/Nc (3). In some cases we were
not able to get a satisfactory parabolic fit of the variance-mean
relationship and we fitted only the initial portion of the graph
with a linear relationship of the form: Iu = σ
2/Im (4). Channel-
gating kinetics were measured from individual power spectra
taken from the steady-state portion of the glycine-induced
current. The one-sided net spectrum (for frequencies < 200Hz)
was fit with a single Lorentzian function and the time constant
τ was calculated from the corner frequency fc according to: τ =
1/ 2pi fc. In some cases, a better fit of the spectra was obtained
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using two Lorentzians and a single weighted time constant τw
was calculated from the two time constants (τ1 and τ2) according
to: τw = τ1 [So1/(So1 + So2)] + τ2 [So2/(So1 + So2)] (5) where
So1 and So2 are the zero frequency spectral power for the two
Lorentzian functions.
RESULTS
Our current view of startle disease focusses on GlyR and
GlyT2 variants either affecting receptor/transporter function or
biogenesis. However, in vivo compensatory mechanisms are
still a matter of debate. Using the spontaneous mouse GlyR
α1 subunit mutant shaky, it has been demonstrated that the
extracellular β8-β9 loop is a key structural and functional element
for GlyR signaling that influences conformational changes
including the M3-M4 domain involved in synaptic clustering
and the formation of the glycine-binding pocket (Schaefer
et al., 2017). Here, we give a detailed genetic, behavioral and
electrophysiological account of this mouse model and investigate
temporal differences between disease onset, GlyR expression and
GlyR function.
The novel murine shaky mutation (GlyR α1Q177K) arose as
a spontaneous mutation in a hybrid background of C57BL6
and 129SvJ (Schaefer et al., 2017). A rapid differentiation
between mouse genotypes was enabled by the disruption of
a HpyCH4V restriction site (Figure 1A). Sequencing of Glra1
from homozygous shakymice (Glra1sh/sh) and littermate controls
revealed two transitions: c.T198C in exon 3 (synonymous,
p.N38N) and c.C613A in exon 6 (missense, p.Q177K, numbers
refer to mature protein) (Figure 1B). The exon 3 transition is due
to to a single nucleotide variation in the background mouse lines
C57BL6 and 129SvJ of the shaky origin (Figure 1B). Although
synonymous at the protein level, nucleotide sequence variations
might disrupt or result in exonic splicing enhancer (ESE) sites
and thus influence splicing events of the affected mRNA (Becker
et al., 2012).
To exclude aberrant splicing, GlyR α1 subunit mRNA was
analyzed for possible ESE sites at sequence variations in exon
3 and exon 6 observed in shaky mice. The sequence of exon
3 harboring the c.T198C transition in exon 3 did not reveal
an ESE site in the wild-type or in the mutated sequence. The
sequence transition in exon 6 corresponded to an ESE site for
the splice factor SRSF1 present in the wild-type but not in the
mutant sequence (http://krainer01.cshl.edu/cgi-bin/tools/ESE3/
esefinder.cgi?process=home). This potential ESE site in the GlyR
α1 nucleotide sequence 611TGCAGGT617 had a score of 2.23402,
threshold: 1.956. However, we did not observe aberrant splicing
of GlyR α1 subunit mRNA (Figure 1C) in either wild-type
(Glra1+/+) or homozygous shaky (Glra1sh/sh) mice.
The phenotype of homozygous shaky mice becomes apparent
at the age of 2 weeks, at the time point when GlyRs containing
the α2 subunit are switched for adult GlyR α1β isoforms in the
spinal cord and brain stem. A severe motor defect characterized
by tremor, muscle spasms, twitchy tail, stiffness, and poor
motor control compared to age-matched littermates becomes
evident. Homozygous shaky mice can be easily recognized by
typical hind feet clasping when picked up by their tails, and
abnormal gait with uneasy footsteps and skidding of hind
limbs during tremor episodes (Figure 2A). These neuromotor
symptoms are similar to oscillator mice (Buckwalter et al.,
1994), a mouse model for startle disease/hyperekplexia with
a progressive severe phenotype. During episodes of tremor,
shaky mice display a hunched, stiff posture and often end up
on the tip of their toes, which causes them to fall over on
their side or back (Videos 1, 2). Homozygous mutant mice
are usually smaller than their littermates with a significant
decrease in body weight observed after P28, 2 weeks after
phenotypic onset (Figure 2B). On average, shaky mice die at
the age of 3–6 weeks. A 100% overlap between genotyped
homozygous shaky mice, the observed typical startle phenotype
and death after 3–6 weeks was observed. Heterozygous shaky
mice were bred to heterozygous oscillator and spasmodic
mice. Homozygous oscillator mice die at the age of 3 weeks,
homozygous spasmodic mice have a normal life span. Again
with a delay to phenotypic symptoms, significantly lower body
weight (P24-32) was determined for Glra1sh/ot mice (Figure 2C).
Backcross experiments of shaky animals into the spasmodic
mouse line led to a mild phenotype and survival of Glra1sh/spd
animals similar to the homozygous spasmodic animals. No
differences in body weight were observed for Glra1sh/spd animals
compared to wild-type controls or heterozygous Glra1+/sh and
Glra1+/spd animals (data not shown). Due to the survival of
Glra1sh/spd animals, we analyzed the expression pattern of the
GlyR α1 subunit during development. Expression of the GlyR
α1 subunits was detected in spinal cord and brainstem samples
from P0 to P28 in backcross experiments of the shaky line into
the spasmodic line.
GlyR α1 subunit expression started at P7 in spinal cord
and in brain stem of Glra1sh/spd animals indistinguishable from
Glra1+/+ mice (Figures 3A–D). No GlyR α1 subunit expression
was observed in cerebral cortex (using a polyclonal antibody
against the N-terminus of the 48 kDa GlyR α1 subunit (dilution
1:200, Merck Millipore, Darmstadt, Deutschland), which served
as a negative control. This does not necessarily mean that other
GlyR α subunits are also not expressed. Previously we have
shown, using a pan-GlyR α subunit antibody, that other GlyR
α subunits are expressed in the cortex of Glra1+/+, Glra1+/sh,
and Glra1sh/sh animals at P28 (Schaefer et al., 2017) although
expression was decreased compared to brainstem and spinal cord
controls. Here, the subunit switch to increased GlyR α1 subunit
levels after birth was completed before onset of symptoms at P14.
Despite a normal life span, Glra1spd/sh mice developed of a startle
phenotype. To determine if symptomatic onset influences GlyR
α1 expression, the GlyR α1 protein was monitored up to P100
demonstrating constant GlyR α1 subunit levels between P14-
P100 (Figure 3B). There were no obvious differences between
symptomatic Glra1spd/sh mice and non-symptomatic Glra1+/sh
and Glra1+/spd animals.
Since the touch-evoked startle and escape behavior in
zebrafish mirrors a startle phenotype in mice or humans, we
used the Dhx37 zebrafish model to analyze the GlyR α1Q177K
mutation. Normally, zebrafish embryos respond to tactile stimuli
with escape contractions that typically consist of two-to-three
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FIGURE 1 | Genotype of shaky mice. (A) The recognition site for the restriction enzyme HpyCH4V is disrupted by the shaky mouse mutation in exon 6; left panel.
PCR genotyping of shaky (Glra1sh/sh ), wild-type (Glra1+/+) and heterozygous (Glra1+/sh ) mice with subsequent HpyCH4V digest (right panel). (B) Sequencing
chromatograms of wild-type strains C57BL6 and 129/SvJ, heterozygous Glra1+/sh, and homozygous Glra1sh/sh showing a c.T198C transition in exon 3 and a
c.C613A transition in exon 6. Both wild-type mouse strains are shown since the shaky mutation arose in a hybrid background of C57BL6 and 129/SvJ. (C) RT-PCR
analysis of GlyR α1 subunit mRNA levels in spinal cord (sc) and brain stem (bs) of wild-type (n = 4) and shaky mice (n = 4). β-actin cDNA was amplified as a reference
gene to ensure equal cDNA content in all samples.
rapid, alternating contractions of the axial muscles (Hirata et al.,
2005). Knockdown of Dhx37 decreases GlyR α subunit mRNAs
(GlyR α1, α3, and α4a subunits) causing abnormal escape
responses in zebrafish (Hirata et al., 2013). The three different
types of escape behavior, normal escape behavior (a lateral turn
and subsequent swimming), a mild version of abnormal escape
behavior (a dorsal bend followed by swimming of more than
2 cm) and the severe change in escape behavior (a dorsal bend
without escape swimming) were compared. Co-injection of GlyR
α1 subunit wild-type RNAs with a morpholino against Dhx37
(MO2-dhx37) increased the normal escape behavior compared
to morpholino alone, while co-injection of GlyR α1Q177K with
MO2-dhx37 was not able to recover normal escape behavior to
the same extent as wild-type GlyR α1 (Figure 4, Table 1). Co-
injection of control RNAs with MO2-dhx37 did not ameliorate
the escape response. These results demonstrate that the GlyR
α1 subunit Q177K mutant is incapable of recovering disrupted
motor phenotypes in zebrafish.
Biochemical analysis revealed no differences in the relative
expression of GlyR α1 subunits in mixed whole-brain and spinal
cord homogenisates of homozygous shaky mice in comparison
to Glra1+/+ mice (n = 3 each genotype). The GlyR α1 amount
was normalized to the control protein β-actin. The wild-type
GlyR α1 value was set to 1 (Figure 5A). These data suggest that
there are no significant differences of the GlyR α1 subunit in
wild-type (relative expression 1.0± 0.37) vs. shakymice (relative
expression 0.63 ± 0.23) when combined brain and spinal cord
samples were analyzed. We also examined the possibility that
the phenotype in shaky mice was due to a loss of motoneurons
in the brain stem, which could also be a cause for the observed
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FIGURE 2 | The neuromotor phenotype of shaky mice is due to a glycinergic
defect. (A) Footprint recordings. Mice painted on their hind paws were placed
on a sheet of paper in a 30 cm tunnel. Representative Glra1+/+ and
Glra1sh/sh footprints are shown at P14 and P22. (B) Homozygous Glra1sh/sh
mice (n = 9) gain less body weight than wild-type (n = 4) and heterozygous
littermates (n = 19). Survival curves of Glra1sh/sh, Glra1+/sh, Glra1+/+ mice.
Glra1sh/sh mice die between weeks 3 and 6 of life. (C) Loss in body weight of
heterozygous Glra1sh/ot mice following onset of symptoms (P14), Glra1+/+ n
= 19, Glra1+/sh n = 9, Glra1+/ot n = 25, Glra1sh/ot n = 10, ANOVA **p <
0.01, ***p < 0.001.
symptoms. Motoneurons were counted in facial nerve in 15–16
sections of every tenth section of the brain stem. However, no
differences in the number of motoneurons were detected in brain
stem nuclei (number of motoneuronsGlra1+/+ 1,317± 169 with
n = 4, Glra1sh/sh 1,424 ± 183 with n = 3) (Figure 5B), which
is in line with previous data demonstrating similar numbers
of spinal cord motoneurons in both genotypes (Schaefer et al.,
2017).
Humans with startle disease are typically treated with
diazepam, a positive allosteric modulator of GABAA receptors.
Therefore, shaky mice were injected with diazepam and the
phenotype of affected mice was compared before and after
treatment. Diazepam treatment indeed resulted in a decrease in
phenotype severity, as evident by improved overall behavior and
enhanced activity, e.g., time spending on back or in the upright
position, resting, grooming, eating (Figure 6). The overall
activities of Glra1+/+ and Glra1sh/sh mice were counted 30min
before and after diazepam injection. While control mice were
less active after diazepam treatment, likely due to the sedative
nature of this drug (Figure 6), shaky mice were more active.
Although shaky mice still lost balance after diazepam treatment,
they were able to right themselves faster (before 13±2min,
after 28±0.3min) after treatment and spent significantly less
time on their sides and backs (before 17 ± 2min, after 1.7 ±
0.3min) (Figure 6). Resting (before 5.3 ± 1.3min, after 1 ±
0.5min), grooming (before 0.6 ± 0.3min, after 4.7 ± 1.6min),
and time spent eating (before 0.3 ± 0.3min, after 8.7 ± 1.3min)
also improved significantly upon treatment with diazepam.
This argues for GABAergic compensation of glycinergic
deficits but importantly demonstrates that GlyR mutant mice
and wild-type mice respond differently to similar doses
of diazepam.
In order to investigate the functionality of glycinergic
signaling at intact in situ synapses, we prepared brain stem
slices from wild-type and shaky mice and performed whole-cell
recordings from hypoglossal motoneurons (HM), which are rich
in GlyR α1 subunit expression and important for respiration.
Specifically, we asked how the shift in GlyR expression during
postnatal development would affect the electrophysiological
properties of synaptic and extrasynaptic GlyRs in HM neurons
before (P9-13) and after onset (P18-24) of symptoms. In voltage-
clamped HM neurons held at−70mV, bath-applied glycine (10–
1,000µM) induced an inward shift of holding current when
recorded with CsCl-filled pipettes (Figure 7A). In Glra1+/+
HMs, the dose-response relationships of glycine currents did
not differ between the two age groups (Glra1+/+, P18-24, n
= 11 from 6 mice; P9-13, Glra1+/+, n = 7 from 4 mice),
with EC50 values of 270µM in P9-13 HMs and 277µM in
P18-24 HMs, respectively (Figures 7B,C). In Glra1sh/sh mice,
however, EC50 values increased from 313µM in P9-13 HMs
to 384µM in P18-24 HMs as shaky mice became symptomatic
(Figures 7B,C; Glra1sh/sh, P18-24, n = 9 from 6 mice; P9-13,
n = 8 from 5 mice). In addition to the reduced efficacy of
externally applied glycine, we found that tonic inhibition by
ambient glycine acting on extrasynaptic GlyRs was abrogated in
slices from Glra1sh/sh HMs (Figure 7D). By contrast, although
the GlyR antagonist strychnine (2µM) revealed substantial tonic
inhibition in Glra1+/+ HMs through its effects on holding
current and current variance, we failed to detect any change
in these parameters upon strychnine application in HMs from
P18-24 Glra1sh/sh mice (Figures 7D,E; Glra1+/+, 24.2 ± 9.6
pA2, n = 6 from 4 mice; Glra1sh/sh, 1.8 ± 1.2 pA2, n = 6
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FIGURE 3 | Backcross of shaky mouse line into the spasmodic mouse line. Developmental expression of the GlyR α1 subunit in shaky mice and after backcross into
the mouse line spasmodic (A–D). After backcross of shaky into the spasmodic line, the expression profile was determined in spinal cord (sc), brain stem (bs) and
cortex (cx) for stages P0, P7, P14, P28, P56, P84, and P100. (A) Glra1+/+, (B) Glra1sh/spd , (C) heterozygous Glra1+/spd , and (D) heterozygous Glra1+/sh. Cortex
(cx) served as negative control for GlyR α1. GlyR α1 subunit was stained with mAb2b (48 kDa), and β-Actin (46 kDa) served as a loading control (LC). Cortex samples
were probed with a GlyR pan-α antibody (mAb4a) labeling other GlyR α subunits in the cortex (A,B).
from 5 mice; p = 0.043). We also performed stationary noise
analysis to examine the amplitude and kinetics of the unitary
events underlying the macroscopic glycine-evoked whole-cell
currents at 100–300µM glycine (Figures 8A–C). We did not
detect any differences in unitary current amplitude, number
of open channels, and noise time constants between Glra1+/+
and Glra1sh/sh mice of either age group. By contrast, the open
probability of channels was significantly reduced in HMs of
older shaky mice compared to wild-type neurons of the same
age.
While current responses to bath-applied glycine or strychnine
reflected predominantly the activation or suppression,
respectively, of extrasynaptic GlyRs, we next examined the
functionality of synaptic GlyRs mediating phasic inhibition
in Glra1+/+ and Glra1sh/sh HMs at both stages of postnatal
development. In the presence of TTX (1µM) and blockers
of ionotropic glutamate receptors (KA, 2mM) and GABAA
receptors (BIC, 10µM), we monitored miniature inhibitory
postsynaptic currents (mIPSCs) arising from spontaneous,
action potential-independent release of glycine from presynaptic
terminals. Compared to Glra1+/+ HMs, mIPSCs recorded in
HMs from P18-24 Glra1sh/sh mice showed a significant decrease
in frequency, amplitude and decay time, but no change in rise
time (Figure 9; Glra1+/+, n = 10 from 5 mice; Glra1sh/sh, n
= 9 from 6 mice). Such strongly diminished mIPSCs have
been also observed in PreBötzinger complex neurons of shaky
mice (Schaefer et al., 2017), demonstrating a widespread
deficiency of glycinergic inhibition in this mouse mutant.
Interestingly, a decline in mIPSC amplitude was already evident
in younger P9-13 mice (Glra1sh/sh mice (Glra1+/+, n = 6 from
3 mice, Glra1sh/sh, n = 6 from 4 mice), arguing for a lack of
compensation by other GlyR subunits at an early stage of the
subunit switch.
DISCUSSION
The shaky mouse model, harboring the GlyR α1 subunit
mutation Q177K, is the first in vivo model revealing that the
integrity of the β8-β9 loop in the ECD is a key regulator of
glycinergic signaling. The neuromotor phenotype of shaky mice
is severe and incompatible with life. Functional impairment
of GlyRs containing the α1 subunit in shaky mice is in line
with structural data of the GlyRs illustrating conformational
rearrangements with coupling of movements within the ECD
(loop C, β1-2, β6-7) upon ligand-binding with elements of the
ECD TMD interface (β10-pre-M1, the M2-3 loop) during GlyR
channel gating processes (Du et al., 2015; Huang et al., 2017).
Moreover, the GlyR α1 subunit structure suggested that the
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FIGURE 4 | The Q177K mutation prevents functional recovery in the zebrafish
mutant Dhx37. Stacked bar diagram representing four different conditions of
morpholino or mRNA injections into zebrafish larvae. MO2-dhx37 is present in
all four conditions. Second lane shows additional injection of a control mRNA,
third line injection of wild-type GlyR α1 subunit mRNA and fourth lane injection
of GlyR α1Q177K mRNA. Black squares demonstrate the portion of severe
escape behavior of zebrafish larvae in percent (%), gray squares display the
portion of the mild phenotype, and red the normal escape behavior. Animals
analyzed for control condition n = 31–38, animals for GlyR α1 wild-type n =
79, GlyR α1Q177K n = 63. P-value represents significance level with *p < 0.05
and ***p < 0.001.
β8-β9 loop of the complementary subunit is localized underneath
the ligand binding domain of two adjacent subunits, mediating
rearrangements required to translate ligand binding into ion
channel opening (Du et al., 2015).
In this study, we have focused on behavioral and functional
disturbances in homozygous shaky mice Glra1sh/sh during
different stages of development: (i) after GlyR α1 subunit
expression starts (P9-13) and (ii) after symptomatic disease onset
(P18-24).
Shaky arose as a spontaneous mutation in a hybrid mouse
background of C57BL6 and 129SvJ lines. Mutant mice become
obvious due to their increased startle, muscle spasms and
rigidity, tremors, abnormal gait starting at the age of postnatal
day 14. These symptoms reflect the phenotype observed in
several other startle disease mouse models, e.g., cincinnati,
nmf11, spasmodic, spastic and oscillator (Schaefer et al., 2012).
DNA sequence analysis of affected homozygous shaky mice
(Glra1sh/sh), and wild-type control animals (Glra1+/+) from both
mouse background lines identified a synonymous variant in exon
3 (c.T198C, N38N) and a missense mutation in exon 6 (c.C613A,
p.Q177K) (Schaefer et al., 2017). A non-synonymous variant,
e.g., in exon 3 (c.T198C, p.N38N) although present in both
mouse backgrounds, does not necessarily mean that the base pair
substitution at the DNA level does not contribute to the observed
phenotype. For example, a single nucleotide polymorphism
present in exon 6 of spastic mice that differed between the
C57BL6 and B6C3Fe mouse lines used as background was
identified as an important exonic splicing enhancer (ESE)
site contributing to aberrant splicing underlying the spastic
phenotype as well as the known insertion of a LINE1 element in
intron 6 of theGlrbmouse model for startle disease (Becker et al.,
2012). ESE analysis of both single nucleotide polymorphisms
identified in shaky mice using the software ESEfinder 3.0 did
not suggest the creation or destruction of an ESE in exon 3.
However, the exon 6 was found to harbor an ESE in the wild-
type sequence that is no longer present in the shaky sequence.
However, no aberrant splicing of GlyR α1 subunit transcripts
was detectable, excluding a splicing defect as a determinant
in the pathomechanism of startle disease in the shaky
mouse model.
Uncoordinated motor behavior and typical hind-limb
clasping were the first visible phenotypic symptoms present
at postnatal day 14. In addition, a longer time window
for righting has been shown for shaky mice (Schaefer
et al., 2017). All together, these symptoms are similar to
symptoms reported in cincinnati, oscillator, nmf11, spasmodic
and spastic mice (Buckwalter et al., 1994; Holland et al.,
2006; Traka et al., 2006; Becker et al., 2012; Schaefer et al.,
2017). Patients are symptomatically treated by diazepam,
a positive allosteric modulator of GABAA receptors
(Praveen et al., 2001). Likewise, the activity pattern of
affected homozygous shaky mice at P28 improved upon
treatment with diazepam. Despite its utility in human
startle disease, the molecular mechanism underlying the
effectiveness of diazepam treatment is not completely
understood.
In zebrafish, mutations within the glycinergic system lead to
a loss of reciprocal inhibition between the left and right sides
of the spinal cord, ending in the activation of motoneurons
simultaneously on both sides (Grillner, 2003; Fetcho et al., 2008),
following bilateral muscle activation and thus dorsal flexure
of the body (Hirata et al., 2005). Mutant alleles beotw38f and
beomi106a harbor different missense mutations in the zebrafish
GlyR β subunit (L255R and R275H, respectively) that result in
impaired escape responses. The R275H mutation in zebrafish
GlyR β affects a highly conserved arginine residue prior to
TM2. The corresponding mutation in the human GlyR α1
subunit, R252H, is known to accelerate degradation of GlyR
α1 resulting in lack of GlyR ion channel function (Rea et al.,
2002; Villmann et al., 2009). The analysis of the β8-β9 loop
mutation GlyR α1Q177K in zebrafish larvae revealed an abnormal
escape response for some animals. The motor phenotype of
the Dhx37 zebrafish model was not recovered with GlyR
α1Q177K mRNA. The observed effect was mild compared to
the murine phenotype and might be explained by the use of
the MO-dhx37 model encoding a RNA helicase involved in
GlyR α1, α3 and α4a subunit mRNA biogenesis and splicing.
In zebrafish, five GlyR α subunits and two β subunit genes
have been reported (David-Watine et al., 1999; Imboden et al.,
2001; Hirata et al., 2005), arguing that GlyR α2, α4b and
βa subunits that are not affected by MO-dhx37 treatment
might contribute to less severity in the zebrafish model. These
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data, however further support the importance of the GlyR
α1 β8-β9 loop for motor behavior shown in another animal
model.
As a consequence of the neurological phenotype, significant
physical changes e.g., body weight become apparent with a
delay of 1–2 weeks following symptomatic onset in shaky
mice. Differences in the initiation of disease symptoms
between humans and mice have been attributed to differences
in developmental regulation of GlyR expression of affected
subunits. In rodents, GlyR α1 transcript has been first observed
at E14 but with very weak signals. Clear signals are detected
at P5 and continuously increase until P14 onwards (Malosio
et al., 1991). At the protein level, it has been suggested that
the developmental shift between neonatal and adult GlyR
isoforms is completed after P21 (Becker et al., 1988). In
neurons of the brain stem, e.g., PreBötC and HM GlyR α1
immunoreactivity was low between P2 and P11, with a slight
peak at P7 and an additional peak that persisted from P12
until P21 (Liu and Wong-Riley, 2013). In humans, patients
with GLRA1 mutations suffer from neonatal hypertonia, an
exaggerated startle reflex in response to tactile or acoustic
stimuli and in some instances in life-threatening infantile apnea
episodes immediately after birth arguing for a developmental
switch of GlyR α2 to α1 subunits around birth (Davies et al.,
2010).
Previously, we found the GlyR α1 protein in spinal cord and
brain stem of wild-type, heterozygous and homozygous shaky
mice at P7 (Schaefer et al., 2017). Here, the GlyR α1 subunit
was clearly detectable at P7 in backcross experiments into the
spasmodic mouse line. Hence, although the developmental shift
between GlyR α1 and α2 subunits starts around P5 in rodents,
shaky mice become phenotypically apparent at postnatal day
14 arguing at least for some compensation by other GlyRs or
GABAARs within the second week of life. Such compensation
by other GlyR α subunits cannot be attributed to an increase
in the expression level of α2 or α3 subunits (Schaefer et al.,
2017). Graham et al. demonstrated GABAergic compensation
in spastic mice (which have lowered expression of the GlyR
β subunit). In contrast, in oscillator mice no GABAergic
compensation was observed (Graham et al., 2003). Recordings
from PreBötC neurons of the brain stem at P18-24 did not reveal
any differences in GABAergic mIPSCs between Glra1sh/sh and
Glra1+/+ animals. Thus, we excluded GABAergic compensation
in shakymice at least at this developmental stage (Schaefer et al.,
2017).
Due to the enhanced muscle tone following acoustic and
tactile trigger starting at P14, physical impairment, e.g., a
reduction in body weight, becomes evident with an additional
week delay. Thus, the questions arises what happens at the
functional level of the GlyR following expression start of
GlyR α1 subunit and after symptomatic disease onset? In
spastic mice, a crosstalk between presynaptic and postsynaptic
elements at different stages of development (P5 and P15)
has been suggested to underlie the pathology (Muller et al.,
2008).
Previously published data in PreBötC neurons of homozygous
shakymice showed reduced GlyR current amplitudes in P18-P24
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FIGURE 5 | Expression level and number of motoneurons in wild-type and
homozygous shaky mice. (A) Western blot analysis of GlyR α1 subunit protein
expression in whole brain and spinal cord homogenates. Normalization with
β-actin showed no significant differences of GlyR α1 protein levels between the
two genotypes (n = 3), right image shows an example of the Western blot
from two different animals of each genotype (Glra1+/+ and Glra1sh/sh ). (B)
Quantitative analysis of motoneuron numbers. The quantification was made
using 3–4 animals of each genotype (Glra1+/+, n = 4; Glra1sh/sh, n = 3).
Right images are examples of brain stem sections from Glra1+/+ and
Glra1sh/sh with arrow heads pointing to motoneurons. Error bars represent
standard deviations (S.D.).
old mice as well as faster ion channel closure when compared
to wild-type neurons (Schaefer et al., 2017). Smaller current
amplitudes of glycinergic mIPSCs have also been detected
in spastic, spasmodic, and oscillator mice (Graham et al.,
2003, 2006). Here, we focused on the functional analysis in
hypoglossal motoneurons (HM) of the brain stem at two stages of
development of shaky mice (P9-P13 and P18-P24). HM neurons
are rich in glycinergic synapses and harbor similar motoneuron
numbers in homozygous shaky mice compared to wild-type
controls.
Patch-clamp recordings revealed significantly reduced
amplitudes of glycinergic mIPSCs in the second postnatal
week, i.e., about 1 week before apparent disease onset. This
pre-symptomatic decline in current amplitude is likely to arise
from the switch to the expression of mutated GlyR α1 which
begins around P7 in shaky animals. In behavioral terms, the
early deficits in GlyR function remain silent for about a week.
However, once the full spectrum of GlyR deficits is achieved
after the second postnatal week, compensatory mechanisms
fail and symptoms appear. Functional compensation by other
subunits seemed to assist during the second week of life, but
failed at later developmental stages (3–6 weeks) when GlyR α2
FIGURE 6 | The neuromotor phenotype of shaky mice improves after
diazepam treatment. Overall activity of Glra1sh/sh (n = 8) mice before and after
diazepam injection is displayed as time spent on a certain activity. The
following activities within a 30min time period were counted: falling (time spent
on back/side vs. upright), resting (defined as the animal sitting in one spot for
more than 10 s without any activity), rearing, grooming, eating/drinking, black
panel Glra1+/+ (n = 4) and red panel Glra1sh/sh mice. Level of significance
**p < 0.01 and ***p < 0.001.
is likely to have been completely replaced by GlyR α1 (Becker
et al., 1988). This is in contrast to spastic mice harboring a
Glrb mutation, which display a compensation by homomeric
α1 subunit GlyRs at extrasynaptic loci (Graham et al., 2011).
Corroborating and extending previous findings from PreBötC
neurons of shakymice (Schaefer et al., 2017), GlyRs of HMs from
mutant mice with overt symptoms recorded between P18-24
showed the following electrophysiological aberrations when
compared to their wild-type counterparts: (i) In addition to
the reduction of mIPSC amplitude already present during the
second postnatal week, we now also observed a dramatically
reduced frequency and a much faster decay of mIPSCs. Such
changes have also been observed in homozygous spasmodic
mice during disease progression (Graham et al., 2006). (ii) Noise
analysis showed that, while the number of GlyR channels and
their unitary current amplitude remained unaffected, their open
probability was significantly reduced. (iii) The dose-response
relationship of GlyR currents to increasing concentrations
of glycine exhibited a pronounced rightward shift leading to
a significantly enhanced EC50 value, and finally, (iv) tonic
glycinergic inhibition through extrasynaptic GlyRs was virtually
abrogated. Thus, while the severe phenotype in shaky mice
clearly results from non-functional postsynaptic α1β subunit
GlyRs, defective extrasynaptic homomeric α1 subunit GlyRs may
also contribute to the phenotype.
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FIGURE 7 | Developmental shift of glycinergic responses in Glra1sh/sh hypoglossal motoneurons. Whole-cell voltage-clamp recordings were obtained from
hypoglossal motoneurons (HMs) held at −70mV, with symmetrical Cl− concentrations inside and outside the cell. (A) Representative traces illustrate reduced glycine
current in a Glra1sh/sh HM (red) when compared to a Glra1+/+ HM (black), both from P18-24 mice. (B) At an earlier postnatal stage (P9-13), dose-response curves
for glycine-induced currents showed no difference between HMs from Glra1+/+ (n = 7) and Glra1sh/sh mice (n = 8). (C) Dose-response curves of Glra1+/+ (n =
6–11) and Glra1sh/sh (n = 8–11) HMs from more mature mice (P18-24) with severe symptoms displayed significant divergence. The EC50 of glycine was significantly
increased in Glra1sh/sh mice. (D) Typical traces from P18-24 HMs illustrate lack of tonic, strychnine (2µM)-sensitive glycine current in mutant HMs. (E) Bar diagrams
summarize loss of glycinergic tone in HMs of Glra1sh/sh mice, as indicated by missing changes in holding current (left columns) and current variance (right columns)
upon application of strychnine. P-value of significance *p < 0.05.
The decline in mIPSC frequency in brain stem slices of
symptomatic shaky mice points to an additional impairment
in glycinergic neurotransmission at the presynaptic site. Other
studies have emphasized the contribution of presynaptic
homomeric GlyR α1 complexes to startle disease (Xiong et al.,
2014). In view of the high intracellular Cl− concentration in
presynaptic terminals, currents through presynaptic GlyRs are
depolarizing. This might in turn activate voltage-dependent
Ca2+ channels and elevate intracellular Ca2+, thereby promoting
transmitter release, as shown for the calyx of Held and
the spinal cord (Turecek and Trussell, 2001; Jeong et al.,
2003). It seems therefore conceivable that, with functionally
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FIGURE 8 | Stationary noise analysis of glycine-evoked whole-cell currents in
wild-type and mutant HMs. (A) Example of a DC whole-cell current response
(top) to glycine in a Glra1+/+ HM (P18-24) and the corresponding AC-coupled
signal (bottom). (B) Variance-mean plot where AC current noise was plotted
against DC current for the traces in (A). The variance (σ2) vs. mean current (I)
relationship was fitted with a parabolic function of the form: σ2 = iI− I2/N to
obtain the unitary current (i) and the number of channels open (N) at the peak
of the current response to glycine. Power spectrum of the glycine-evoked
current noise in (A) was fit with a single Lorentzian function, and the time
constant was calculated from the cut-off frequency fc according to:
τ = 1/2π fc. Points above 200Hz have been omitted, right panel in (B). (C)
Comparisons of unitary currents (P9-13 Glra1+/+ n = 7, Glra1sh/sh n = 5;
P18-24 Glra1+/+ n = 9, Glra1sh/sh n = 7), channel open probability (Popen)
(P9-13 Glra1+/+ n = 4, Glra1sh/sh n = 6; P18-24 Glra1+/+ n = 7, Glra1sh/sh
n = 9), number of channels open at the peak current (P9-13 Glra1+/+ n = 4,
Glra1sh/sh n = 6; P18-24 Glra1+/+ n = 7, Glra1sh/sh n = 9), and noise time
constants (derived from power spectral density analysis) (P9-13 Glra1+/+ n =
10, Glra1sh/sh n = 12; P18-24 Glra1+/+ n = 16, Glra1sh/sh n = 15). Note
that Popen was significantly lower in Glra1
sh/sh mice in the older age group
compared to Glra1+/+ control. *p < 0.05.
impaired homomeric GlyR α1Q177K at the presynaptic site,
transmitter release in shaky mice might be substantially
affected.
Recent work also revealed novel roles of presynaptic GlyRs
outside the brainstem. Functional presynaptic GlyRs were
demonstrated at mossy fiber terminals in the hippocampus at
FIGURE 9 | Developmental shift of glycinergic synaptic inhibition in Glra1sh/sh
HMs. (A) Representative traces from a Glra1+/+ HM and a Glra1sh/sh HM at
P18-24 illustrate miniature IPSCs (mIPSCs). Recordings were performed in the
presence of TTX (1µM), KA (2mM) and bicuculline (10µM). The
superimposed traces on the right are the averaged mIPSCs from respective
neurons on the left. (B–E) Bar diagrams summarize the changes of mIPSC
kinetics in Glra1sh/sh mice. Note that a change in mIPSC amplitude was
already apparent in Glra1sh/sh mice at P9-13 when the receptor replacement
has already started but neuromotor symptoms have not yet appeared.
Dramatic reductions in (B) mIPSC frequency (P9-13 Glra1+/+ n = 6,
Glra1sh/sh n = 6; P18-24 Glra1+/+ n = 9, Glra1sh/sh n = 9), (C) amplitudes
(P9-13 Glra1+/+ n = 6, Glra1sh/sh n = 6; P18-24 Glra1+/+ n = 9, Glra1sh/sh
n = 9), and (E) decay (P9-13 Glra1+/+ n = 6, Glra1sh/sh n = 6; P18-24
Glra1+/+ n = 10, Glra1sh/sh n = 9) were uniformly observed in HMs from
P18-24 Glra1sh/sh mice. (D) Rise time constants (P9-13 Glra1+/+ n = 6,
Glra1sh/sh n = 6; P18-24 Glra1+/+ n = 10, Glra1sh/sh n = 9). *p < 0.05.
mossy fiber terminals mainly during postnatal development
(Kubota et al., 2010). Using gain-of-function GlyR α3 subunit
mutants, their impact on hippocampal network activity and
related behaviors and diseases was established (Winkelmann
et al., 2014; Çaliskan et al., 2016). Since glycinergic effects in
the hippocampus are likely to be mediated by GlyRs containing
α2 and α3, but not α1 subunits, the shaky α1 mutant is
unlikely to alter the presynaptic actions of glycine in the
hippocampus.
Presynaptic compensation by other GlyR subtypes might
maintain glycinergic inhibition to some extent during the second
postnatal week until homomeric neonatal GlyRs are down-
regulated to make way for adult α1β GlyRs that are no longer
able to sustain glycinergic inhibition.
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In summary, we have demonstrated that the shaky mutation
in the GlyR α1 subunit results in defective synaptic integration,
incomplete compensation and functional disturbances that
are incompatible with survival. We have also provided
novel insights into the pathogenesis of startle disease by
demonstrating that motor disturbances and functional
deficits at synapses can be observed prior to the onset of
severe symptoms. Lastly, we have shown the deficits in
presynaptic GlyR function are also apparent in shaky mice,
suggesting that deficits in presynaptic glycine release, as
well as postsynaptic GlyR function, contribute to startle
disease.
AUTHOR CONTRIBUTIONS
AB performed transcript analysis. AB and NS conducted animal
behavioral tests. HH conducted zebrafish studies. SL and RH
performed sequencing analysis of genomic DNA. NS conducted
mouse backcrosses with other GlyR mutant mouse lines. NS
conducted counting of motoneurons. FZ and JvB conducted
patch clamp recordings in brain stem slices. NS and CV
performed protein analyses from mouse tissues. NS, CV, AB, FZ,
JvB, and HH performed data analyses. NS, CP, CA, RH, and CV
participated in manuscript writing. CV initiated, designed and
supervised the project.
FUNDING
This work was supported by DFG VI586 (CV), Terry Fox
Foundation and Canadian Institutes for Health Research
(CP), Grant-in-aid for Scientific Research on Innovative
Areas 17H05578 from Japan Society for the Promotion
of Science (HH), The Naito Foundation (HH), The
Japan Epilepsy Research Foundation (HH), and the MRC
(MR/J004049/1 to RH). NS was supported by the Scientia-
carrier development program, University of Würzburg.
The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the
manuscript.
ACKNOWLEDGMENTS
We would like to thank Katrin Walter for excellent technical
assistance. Sibylle Jablonka is acknowledged for her advice with
motoneuron counting and analysis.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fnmol.
2018.00167/full#supplementary-material
REFERENCES
Althoff, T., Hibbs, R. E., Banerjee, S., and Gouaux, E. (2014). X-ray structures of
GluCl in apo states reveal a gating mechanism of Cys-loop receptors. Nature
512, 333–337. doi: 10.1038/nature13669
Becker, C. M., Hoch, W., and Betz, H. (1988). Glycine receptor heterogeneity in rat
spinal cord during postnatal development. EMBO J. 7, 3717–3726.
Becker, K., Braune, M., Benderska, N., Buratti, E., Baralle, F., Villmann, C., et al.
(2012). A retroelementmodifies pre-mRNA splicing: themurineGlrbspa allele is
a splicing signal polymorphism amplified by long interspersed nuclear element
insertion. J. Biol. Chem. 287, 31185–31194. doi: 10.1074/jbc.M112.375691
Buckwalter, M. S., Cook, S. A., Davisson, M. T., White, W. F., and Camper, S. A.
(1994). A frameshift mutation in the mouse α1 glycine receptor gene (Glra1)
results in progressive neurological symptoms and juvenile death. Hum. Mol.
Genet. 3, 2025–2030. doi: 10.1093/hmg/3.11.2025
Çaliskan, G., Müller, I., Semtner, M., Winkelmann, A., Raza, A. S., Hollnagel,
J. O., et al. (2016). Identification of parvalbumin interneurons as cellular
substrate of fear memory persistence. Cereb. Cortex 26, 2325–2340.
doi: 10.1093/cercor/bhw001
Christian, C. A., Herbert, A. G., Holt, R. L., Peng, K., Sherwood, K. D.,
Pangratz-Fuehrer, S., et al. (2013). Endogenous positive allosteric modulation
of GABAA receptors by diazepam binding inhibitor. Neuron 78, 1063–1074.
doi: 10.1016/j.neuron.2013.04.026
David-Watine, B., Goblet, C., de Saint Jan, D., Fucile, S., Devignot, V., Bregestovski,
P., et al. (1999). Cloning, expression and electrophysiological characterization
of glycine receptor α subunit from zebrafish. Neuroscience 90, 303–317.
doi: 10.1016/S0306-4522(98)00430-8
Davies, J. S., Chung, S. K., Thomas, R. H., Robinson, A., Hammond, C. L., Mullins,
J. G., et al. (2010). The glycinergic system in human startle disease: a genetic
screening approach. Front. Mol. Neurosci. 3:8. doi: 10.3389/fnmol.2010.00008
Deckert, J., Weber, H., Villmann, C., Lonsdorf, T. B., Richter, J., Andreatta,
M., et al. (2017). GLRB allelic variation associated with agoraphobic
cognitions, increased startle response and fear network activation: a potential
neurogenetic pathway to panic disorder. Mol. Psychiatry. 22, 1431–1439.
doi: 10.1038/mp.2017.2
Du, J., Lü, W., Wu, S., Cheng, Y., and Gouaux, E. (2015). Glycine receptor
mechanism elucidated by electron cryo-microscopy. Nature 526, 224–229.
doi: 10.1038/nature14853
Fetcho, J. R., Higashijima, S., and McLean, D. L. (2008). Zebrafish
and motor control over the last decade. Brain Res. Rev. 57, 86–93.
doi: 10.1016/j.brainresrev.2007.06.018
Ganser, L. R., Yan, Q., James, V. M., Kozol, R., Topf, M., Harvey, R. J., et al. (2013).
Distinct phenotypes in zebrafish models of human startle disease. Neurobiol.
Dis. 60, 139–151. doi: 10.1016/j.nbd.2013.09.002
Graham, B. A., Schofield, P. R., Sah, P., and Callister, R. J. (2003). Altered
inhibitory synaptic transmission in superficial dorsal horn neurones in spastic
and oscillator mice. J. Physiol. 551, 905–916. doi: 10.1113/jphysiol.2003.049064
Graham, B. A., Schofield, P. R., Sah, P., Margrie, T. W., and Callister, R. J.
(2006). Distinct physiological mechanisms underlie altered glycinergic synaptic
transmission in the murine mutants spastic, spasmodic, and oscillator. J.
Neurosci. 26, 4880–4890. doi: 10.1523/JNEUROSCI.3991-05.2006
Graham, B. A., Tadros, M. A., Schofield, P. R., and Callister, R. J. (2011). Probing
glycine receptor stoichiometry in superficial dorsal horn neurones using
the spasmodic mouse. J. Physiol. 589, 2459–2474. doi: 10.1113/jphysiol.2011.
206326
Grillner, S. (2003). The motor infrastructure: from ion channels to neuronal
networks. Nat. Rev. Neurosci. 4, 573–586. doi: 10.1038/nrn1137
Harvey, R. J., Depner, U. B., Wässle, H., Ahmadi, S., Heindl, C., Reinold, H., et al.
(2004). GlyR α3: an essential target for spinal PGE2-mediated inflammatory
pain sensitization. Science 304, 884–887. doi: 10.1126/science.1094925
Harvey, R. J., Topf, M., Harvey, K., and Rees, M. I. (2008). The genetics
of hyperekplexia: more than startle! Trends Genet. 24, 439–447.
doi: 10.1016/j.tig.2008.06.005
Hibbs, R. E., and Gouaux, E. (2011). Principles of activation and
permeation in an anion-selective Cys-loop receptor. Nature 474, 54–60.
doi: 10.1038/nature10139
Hirata, H., Ogino, K., Yamada, K., Leacock, S., and Harvey, R. J. (2013).
Defective escape behavior in DEAH-box RNA helicase mutants improved
by restoring glycine receptor expression. J. Neurosci. 33, 14638–14644.
doi: 10.1523/JNEUROSCI.1157-13.2013
Frontiers in Molecular Neuroscience | www.frontiersin.org 14 May 2018 | Volume 11 | Article 167
Schaefer et al. Pathology of the GlyR Shaky Mutant
Hirata, H., Saint-Amant, L., Downes, G. B., Cui, W. W., Zhou, W., Granato, M.,
et al. (2005). Zebrafish bandoneon mutants display behavioral defects due to a
mutation in the glycine receptor β-subunit. Proc. Natl. Acad. Sci. U.S.A. 102,
8345–8350. doi: 10.1073/pnas.0500862102
Holland, K. D., Fleming, M. T., Cheek, S., Moran, J. L., Beier, D. R., andMeisler, M.
H. (2006).De novo exon duplication in a new allele of mouseGlra1 (Spasmodic).
Genetics 174, 2245–2247. doi: 10.1534/genetics.106.065532
Huang, X., Chen, H., Michelsen, K., Schneider, S., and Shaffer, P. L. (2015). Crystal
structure of human glycine receptor-α3 bound to antagonist strychnine.Nature
526, 277–280. doi: 10.1038/nature14972
Huang, X., Shaffer, P. L., Ayube, S., Bregman, H., Chen, H., Lehto, S. G.,
et al. (2017). Crystal structures of human glycine receptor α3 bound to a
novel class of analgesic potentiators. Nat. Struct. Mol. Biol. 24, 108–113.
doi: 10.1038/nsmb.3329
Imboden, M., Devignot, V., Korn, H., and Goblet, C. (2001). Regional distribution
of glycine receptor messenger RNA in the central nervous system of zebrafish.
Neuroscience 103, 811–830. doi: 10.1016/S0306-4522(00)00576-5
Jeong, H. J., Jang, I. S., Moorhouse, A. J., and Akaike, N. (2003). Activation
of presynaptic glycine receptors facilitates glycine release from presynaptic
terminals synapsing onto rat spinal sacral dorsal commissural nucleus neurons.
J. Physiol. 550, 373–383. doi: 10.1113/jphysiol.2003.041053
Kubota, H., Alle, H., Betz, H., andGeiger, J. R. (2010). Presynaptic glycine receptors
on hippocampal mossy fibers. Biochem. Biophys. Res. Commun. 393, 587–591.
doi: 10.1016/j.bbrc.2010.02.019
Leacock, S., Syed, P., James, V. M., Bode, A., Kawakami, K., Keramidas, A., et al.
(2018). Structure/function studies of the α4 subunit reveal evolutionary loss of
a GlyR subtype involved in startle and escape responses. Front. Mol. Neurosci.
11:23. doi: 10.3389/fnmol.2018.00023
Liu, Q., and Wong-Riley, M. T. (2013). Postnatal development of glycine
receptor subunits α1, α2, α3, and β immunoreactivity in multiple brain
stem respiratory-related nuclear groups of the rat. Brain Res. 1538, 1–16.
doi: 10.1016/j.brainres.2013.09.028
Lynch, J. W. (2004). Molecular structure and function of the glycine receptor
chloride channel. Physiol. Rev. 84, 1051–1095. doi: 10.1152/physrev.00042.2003
Malosio, M. L., Marquèze-Pouey, B., Kuhse, J., and Betz, H. (1991). Widespread
expression of glycine receptor subunit mRNAs in the adult and developing rat
brain. EMBO J. 10, 2401–2409.
Manzke, T., Niebert, M., Koch, U. R., Caley, A., Vogelgesang, S., Hülsmann, S.,
et al. (2010). Serotonin receptor 1A-modulated phosphorylation of glycine
receptor α3 controls breathing in mice. J. Clin. Invest. 120, 4118–4128.
doi: 10.1172/JCI43029
Masu, Y., Wolf, E., Holtmann, B., Sendtner, M., Brem, G., and Thoenen, H. (1993).
Disruption of the CNTF gene results in motor neuron degeneration. Nature
365, 27–32. doi: 10.1038/365027a0
Muller, E., Le Corronc, H., Scain, A. L., Triller, A., and Legendre, P. (2008). Despite
GABAergic neurotransmission, GABAergic innervation does not compensate
for the defect in glycine receptor postsynaptic aggregation in spasticmice. Eur.
J. Neurosci. 27, 2529–2541. doi: 10.1111/j.1460-9568.2008.06217.x
Patrizio, A., Renner, M., Pizzarelli, R., Triller, A., and Specht, C. G.
(2017). α subunit-dependent glycine receptor clustering and regulation
of synaptic receptor numbers. Sci. Rep. 7:10899. doi: 10.1038/s41598-017-
11264-3
Pilorge, M., Fassler, C., Le Corronc, H., Potey, A., Bai, J., De Gois, S., et al.
(2015). Genetic and functional analyses demonstrate a role for abnormal
glycinergic signaling in autism. Mol. Psychiatry 21, 936–945. doi: 10.1038/mp.
2015.139
Pless, S. A., Hanek, A. P., Price, K. L., Lynch, J. W., Lester, H. A., Dougherty, D. A.,
et al. (2011). A cation-pi interaction at a phenylalanine residue in the glycine
receptor binding site is conserved for different agonists. Mol. Pharmacol. 79,
742–748. doi: 10.1124/mol.110.069583
Praveen, V., Patole, S. K., and Whitehall, J. S. (2001). Hyperekplexia in neonates.
Postgrad. Med. J. 77, 570–572. doi: 10.1136/pmj.77.911.570
Rea, R., Tijssen, M. A., Herd, C., Frants, R. R., and Kullmann, D. M.
(2002). Functional characterization of compound heterozygosity for GlyR α1
mutations in the startle disease hyperekplexia. Eur. J. Neurosci. 16, 186–196.
doi: 10.1046/j.1460-9568.2002.02054x
Ryan, S. G., Buckwalter, M. S., Lynch, J. W., Handford, C. A., Segura, L., Shiang,
R., et al. (1994). A missense mutation in the gene encoding the α1 subunit of
the inhibitory glycine receptor in the spasmodicmouse. Nat. Genet. 7, 131–135.
doi: 10.1038/ng0694-131
Ryan, S. G., Sherman, S. L., Terry, J. C., Sparkes, R. S., Torres, M. C., and Mackey,
R. W. (1992). Startle disease, or hyperekplexia: response to clonazepam and
assignment of the gene (STHE) to chromosome 5q by linkage analysis. Ann.
Neurol. 31, 663–668. doi: 10.1002/ana.410310615
Schaefer, N., Berger, A., van Brederode, J., Zheng, F., Zhang, Y., Leacock,
S., et al. (2017). Disruption of a structurally important extracellular
element in the glycine receptor leads to decreased synaptic integration
and signaling resulting in severe startle disease. J. Neurosci. 37, 7948–7961.
doi: 10.1523/JNEUROSCI.0009-17.2017
Schaefer, N., Vogel, N., and Villmann, C. (2012). Glycine receptor mutants of
the mouse: what are possible routes of inhibitory compensation? Front. Mol.
Neurosci. 5:98. doi: 10.3389/fnmol.2012.00098
Schindelin, J., Rueden, C. T., Hiner, M. C., and Eliceiri, K. W. (2015). The ImageJ
ecosystem: an open platform for biomedical image analysis. Mol. Reprod. Dev.
82, 518–529. doi: 10.1002/mrd.22489
Sontheimer, H., Becker, C. M., Pritchett, D. B., Schofield, P. R., Grenningloh, G.,
Kettenmann, H., et al. (1989). Functional chloride channels by mammalian
cell expression of rat glycine receptor subunit. Neuron 2, 1491–1497.
doi: 10.1016/0896-6273(89)90195-5
Traka, M., Seburn, K. L., and Popko, B. (2006). Nmf11 is a novel ENU-induced
mutation in the mouse glycine receptor α1 subunit. Mamm. Genome 17,
950–955. doi: 10.1007/s00335-006-0020-z
Turecek, R., and Trussell, L. O. (2001). Presynaptic glycine receptors enhance
transmitter release at a mammalian central synapse. Nature 411, 587–590.
doi: 10.1038/35079084
Villmann, C., Oertel, J., Melzer, N., and Becker, C. M. (2009). Recessive
hyperekplexia mutations of the glycine receptor α1 subunit affect
cell surface integration and stability. J. Neurochem. 111, 837–847.
doi: 10.1111/j.1471-4159.2009.06372.x
Wilkins, M. E., Caley, A., Gielen, M. C., Harvey, R. J., and Smart, T. G.
(2016). Murine startle mutant Nmf11 affects the structural stability of the
glycine receptor and increases deactivation. J. Physiol. 594, 3589–3607.
doi: 10.1113/JP272122
Winkelmann, A., Maggio, N., Eller, J., Caliskan, G., Semtner, M., Häussler, U.,
et al. (2014). Changes in neural network homeostasis trigger neuropsychiatric
symptoms. J. Clin. Invest. 124, 696–711. doi: 10.1172/JCI71472
Xiong, W., Chen, S. R., He, L., Cheng, K., Zhao, Y. L., Chen, H., et al. (2014).
Presynaptic glycine receptors as a potential therapeutic target for hyperekplexia
disease. Nat. Neurosci. 17, 232–239. doi: 10.1038/nn.3615
Yang, Z., Taran, E., Webb, T. I., and Lynch, J. W. (2012). Stoichiometry and
subunit arrangement of α1β glycine receptors as determined by atomic force
microscopy. Biochemistry 51, 5229–5231. doi: 10.1021/bi300063m
Zhang, Y., Ho, T. N. T., Harvey, R. J., Lynch, J. W., and Keramidas,
A. (2017). Structure-function analysis of the GlyR α2 subunit autism
mutation p.R323L reveals a gain-of-function. Front. Mol. Neurosci. 10:158.
doi: 10.3389/fnmol.2017.00158
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Schaefer, Zheng, van Brederode, Berger, Leacock, Hirata, Paige,
Harvey, Alzheimer and Villmann. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) and the
copyright owner are credited and that the original publication in this journal is cited,
in accordance with accepted academic practice. No use, distribution or reproduction
is permitted which does not comply with these terms.
Frontiers in Molecular Neuroscience | www.frontiersin.org 15 May 2018 | Volume 11 | Article 167
